(Q54290863)

27 May 2018

title

Acute renal failure with preserved renal plasma flow induced by cancer immunotherapy. (English)

1 reference

27 May 2018

1 reference

Mercatello A

1

1 reference

27 May 2018

Hadj-Aïssa A

2

1 reference

27 May 2018

Négrier S

3

1 reference

27 May 2018

Allaouchiche B

4

1 reference

27 May 2018

Coronel B

5

1 reference

27 May 2018

Tognet E

6

1 reference

27 May 2018

Bret M

7

1 reference

27 May 2018

Favrot M

8

1 reference

27 May 2018

Pozet N

9

1 reference

27 May 2018

Moskovtchenko JF

10

1 reference

27 May 2018

language of work or name

English

0 references

publication date

1 August 1991

1 reference

27 May 2018

published in

Kidney International

1 reference

27 May 2018

volume

40

1 reference

27 May 2018

issue

2

1 reference

27 May 2018

page(s)

309-314

1 reference

27 May 2018

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Nephrotoxicity of continuous intravenous infusion of recombinant interleukin-2

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Effects of interleukin-2 immunotherapy on renal function

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Regulation of the immune response by prostaglandins

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Antigravity suit inflation: kidney function and cardiovascular and hormonal responses in men

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Acute renal failure after analgesic drugs including paracetamol (acetaminophen)

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Misoprostol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Clinical toxicity of interferons in cancer patients: a review

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Nephrotic syndrome during treatment with interferon

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1)

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Cardiorespiratory effects of immunotherapy with interleukin-2.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Prospective effect of norepinephrine infusion in acute renal insufficiency induced by interleukin 2 therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Regulation of renal hemodynamics and glomerular filtration in patients with renovascular hypertension during converting enzyme inhibition with captopril

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Interleukin-2 initiates metabolic responses associated with critical illness in humans

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Comparison of hemodynamic and regional blood flow changes at equivalent stages of endotoxin and hemorrhagic shock

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Renal blood flow distribution in septic hyperdynamic pigs

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Distribution of intrarenal blood flow during bacterial Sepsis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Nephrotic syndrome associated with recombinant interleukin-2

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Cachectin/tumour necrosis factor

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

DIRECT RENAL VASODILATATION PRODUCED BY DOPAMINE IN THE DOG.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1991.215

7 January 2021

Identifiers

DOI

10.1038/KI.1991.215

1 reference

27 May 2018

1 reference

27 May 2018